

October 1, 2018

**ONO Announces Transfer of 11 Long-listed Products (5 Brands: Injection)
to Maruishi in Japan**

Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President, Representative Director: Gyo Sagara, “ONO”) announced today that it has agreed to transfer the manufacturing and marketing approval authorization for the following 11 long-listed products (5 brands: injection) to Maruishi Pharmaceutical Co., Ltd. (Osaka, Japan; President: Keiichi Inoue, “Maruishi”).

While ONO and Maruishi will cooperate to ensure and complete the smooth transfer without delay from now on, Maruishi is scheduled to initiate to manufacture and market the concerned products and provide healthcare institutes with these products information as from December 1, 2018. In addition, ONO will transfer to Maruishi the rights of the license and supply agreement on these concerned products and the bulk substances with ONO’s overseas collaboration companies.

ONO is an R&D-oriented pharmaceutical company concentrating its management resources on the discovery, development and commercialization of new drugs. The products to be transferred to Maruishi this time are the first-in-class ethical drugs discovered and developed by ONO and those used for the treatment of many patients for over the long year period. In association with this transfer, ONO aims at further sustained growth by focusing on new drug development without dispersing management resources.

The impact of this transfer on the consolidated financial results for the fiscal year ending March 2019 is expected to be minimal.

Products to be transferred:

| Product name | Therapeutic category |
|---|---|
| Cataclot® 20mg for Injection | Thromboxane synthetase inhibitor |
| Cataclot® 40mg for Injection | |
| Cataclot® Injection 20mg | |
| Cataclot® Injection 40mg | |
| FOY® 100 for Injection | Protease inhibitor |
| FOY® 500 for Injection | |
| Elaspol® 100 for Injection | Neutrophil elastase inhibitor |
| Prostarmon® · F Injection 1000 | Prostaglandin F _{2α} preparation |
| Prostarmon® · F Injection 2000 | |
| Prostandin® for Injection 20μg | Prostaglandin E ₁ preparation |
| Prostandin® for Intravenous Injection 500μg | |

About Ono Pharmaceutical Co., Ltd.

Ono Pharmaceutical Co., Ltd., headquartered in Osaka, is an R&D-oriented pharmaceutical company committed to creating innovative medicines in specific fields, centered on oncology and diabetes. For further information, please refer to the company's website at www.ono.co.jp/eng.

About Maruishi Pharmaceutical Co., Ltd.

Maruishi Pharmaceutical Co., Ltd. has been proactively engaged in a wide range of R&D of pharmaceutical products to ease the pain associated with disease of patients, as a specialty pharma in the perioperative and infection control fields, with ultimate aim to improve the quality-of-life (QOL) of patients. For more information, please visit www.maruishi-pharm.co.jp.

Contact

ONO PHARMACEUTICAL CO., LTD.

Corporate Communications

public_relations@ono.co.jp